9-cis-UAB30

9-cis-UAB30 is a rexinoid agonist. 9-cis-UAB30 significantly decreases the proliferation, viability, and motility of both patient-derived xenografts (PDXs) . 9-cis-UAB30 induced cell-cycle arrest as demonstrated by the significant increase in the percentage of cells in G1 and a decrease in the percentage of cells in S phase by downregulating SKP2 and/or 20S proteasome activity, which leads to increased p27kip1 protein stability. 9-cis-UAB30 downregulates the abundance of stem cell marker mRNAs (Oct4, Nanog, Sox2, nestin) and upregulates the abundance of differentiation marker mRNAs (β3-tubulin, NSE, HOXC9, GAP43) . 9-cis-UAB30 has no adverse effects on the central nervous system and cardiovascular system at the tested dose. 9-cis-UAB30 can be used for the study of neuroblastoma, cutaneous T-cell lymphomas, and breast cancer[1][2][3].

Product Specifications

CAS Number

[205252-57-9]

Product Name Alternative

(9Z) -UAB-30

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

E1/E2/E3 Enzyme; Microtubule/Tubulin; Oct3/4; Proteasome

Related Pathways

Cell Cycle/DNA Damage; Cytoskeleton; Metabolic Enzyme/Protease; Stem Cell/Wnt

Field of Research

Cancer; Neurological Disease

Smiles

O=C(O)/C=C(C)/C=C/C=C(C)\C=C1CCCC2=C/1C=CC=C2

Molecular Formula

C20H22O2

Molecular Weight

294.39

Precautions

P261-P280-P302+P352

References & Citations

[1]Marayati R, et al. 9-cis-9-cis-UAB30, a novel rexinoid agonist, decreases tumorigenicity and cancer cell stemness of human neuroblastoma patient-derived xenografts. Transl Oncol. 2021 Jan;14 (1) :100893.|[2]Chou CF, et al. The retinoid X receptor agonist, 9-cis UAB30, inhibits cutaneous T-cell lymphoma proliferation through the SKP2-p27kip1 axis. J Dermatol Sci. 2018 Jun;90 (3) :343-356.|[3]Lindeblad M, et al. Assessment of oral toxicity and safety of 9-cis-UAB30, a potential chemopreventive agent, in rat and dog studies. Drug Chem Toxicol. 2011 Jul;34 (3) :300-10.|[4]Kapetanovic IM, et al. Murine oncogenicity and pharmacokinetics studies of 9-cis-UAB30, an RXR agonist, for breast cancer chemoprevention. Int J Toxicol. 2010 Mar-Apr;29 (2) :157-64.